Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Revenue of Amarin Corporation plc (AMRN)
Revenue in 2023 (TTM): $308.1 M
According to Amarin Corporation plc's latest financial reports the company's current revenue (TTM) is $308.1 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Amarin Corporation plc
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $308.1 M | $202.59 M | $-14,478,910 | $-53,878,028 | $-59,341,122 |
| 2022 | $369.19 M | $242.48 M | $-90,264,000 | $-103,805,000 | $-105,803,000 |
| 2021 | $583.19 M | $461.86 M | $25.14 M | $11.29 M | $7.73 M |
| 2020 | $614.06 M | $482.62 M | $-14,650,000 | $-17,255,000 | $-18,000,000 |
| 2019 | $429.76 M | $333.74 M | $-15,855,000 | $-22,481,000 | $-22,645,000 |
| 2018 | $229.21 M | $174.67 M | $-108,551,000 | $-116,349,000 | $-116,445,000 |
| 2017 | $181.1 M | $136.15 M | $-44,344,000 | $-54,818,000 | $-67,865,000 |
| 2016 | $130.08 M | $95.72 M | $-66,108,000 | $-76,381,000 | $-86,350,000 |
| 2015 | $81.76 M | $53.88 M | $-98,450,000 | $-118,290,000 | $-115,204,000 |
| 2014 | $54.2 M | $33.72 M | $-92,228,000 | $-59,201,000 | $-56,364,000 |
| 2013 | $26.35 M | $14.44 M | $-179,510,000 | $-169,421,000 | $-166,227,000 |
| 2012 | $ | $ | $-116,184,000 | $-170,068,000 | $-179,184,000 |
| 2011 | $ | $ | $-43,854,000 | $-66,610,000 | $-69,126,000 |
| 2010 | $ | $ | $159.92 M | $-250,090,000 | $-249,589,000 |
| 2009 | $ | $ | $-29,567,000 | $-59,757,000 | $-59,317,000 |
| 2008 | $ | $ | $-18,302,000 | $-20,695,000 | $-20,021,000 |
| 2007 | $7.37 M | $7.37 M | $-32,190,000 | $-39,034,000 | $-38,197,000 |
| 2006 | $500 K | $500 K | $-31,404,000 | $-27,719,000 | $-26,920,000 |
| 2005 | $500 K | $500 K | $-16,794,000 | $-19,405,000 | $-18,707,000 |
| 2004 | $1.02 M | $910 K | $-33,662,000 | $11.35 M | $4.01 M |
| 2003 | $7.37 M | $-4,547,000 | $-53,951,000 | $-26,580,000 | $-19,224,000 |
| 2002 | $65.51 M | $35.38 M | $4.21 M | $-33,545,000 | $-37,084,000 |
| 2001 | $53.77 M | $32.32 M | $16.11 M | $-4,712,000 | $-4,760,000 |
| 2000 | $17.55 M | $12.33 M | $-501,000 | $-2,222,000 | $2.36 M |
| 1999 | $11.22 M | $8.24 M | $-3,041,000 | $-10,150,000 | $4.37 M |
| 1998 | $19 M | $15.3 M | $-1,700,000 | $-30,100,000 | $-28,800,000 |
| 1997 | $24.3 M | $21.5 M | $-3,800,000 | $-11,300,000 | $-7,700,000 |
| 1996 | $21.5 M | $17.5 M | $-18,800,000 | $-16,700,000 | $-15,600,000 |
| 1995 | $29.1 M | $24.2 M | $4.7 M | $5.5 M | $4.1 M |
| 1994 | $18.7 M | $18.7 M | $18.7 M | $ | $2.8 M |
| 1993 | $14.7 M | $11.6 M | $1.4 M | $1.3 M | $900 K |